Improving Outcomes for Patients With Epidermal Necrolysis

• Autores: Robert G. Micheletti, Megan H. Noe
• Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 156, Nº. 12, 2020, págs. 1289-1290
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Epidermal necrolysis (EN), encompassing the spectrum of Stevens-Johnson syndrome and toxic EN, is a rare, severe cutaneous drug reaction with an estimated mortality in modern cohorts of 15% to 23%.1-3 The rarity of the disease makes rigorous prospective clinical research difficult, highlighting the need for multicenter, multinational collaborations as well as iterative efforts to validate and build on prior work.